Pancreatic carcinoma is one of the most aggressive tumor entities, and standard chemotherapy provides only modest benefit. Therefore, specific targeting of pancreatic cancer for early diagnosis and therapeutic intervention is of great interest. We have previously shown that the cellular receptor for Shiga toxin B (STxB), the glycosphingolipid globotriaosyl ceramide (Gb 3 or CD77) is strongly increased in colorectal adenocarcinoma and their metastases. Here, we report an up-regulation of Gb 3 in pancreatic adenocarcinoma (21 of 27 cases), as compared to matched normal tissue (n=27). The mean expression was highly significantly increased, from 30 ± 16 ng Gb 3 per mg tissue in normal pancreas to 61 ± 41 ng Gb 3 per mg tissue (mean ± SD, p = 0.0006), as evidenced by thin layer chromatography. Up-regulation of Gb 3 -levels did not depend on tumor stage or grading, and showed no correlation with clinical outcome.
INTRODUCTION
Pancreatic carcinoma is one of the most aggressive tumor entities with a median survival of 6 months and a 5-year survival of less than 5% (1) . Curative resection often is not possible due to late diagnosis of the tumor, and the current standard chemotherapy with gemcitabine has increased the overall survival only modestly (2, 3) . The targeting of pancreatic cancer for early diagnosis, e.g. by imaging methods, and for therapeutic purposes, e.g., by specific delivery of cytotoxic compounds to pancreatic tumor cells, is therefore of great clinical interest. The non-toxic B-subunit of the bacterial Shiga toxin (STxB) is a promising new option for diagnosis and therapy of gastrointestinal tumors. We and others showed previously that the expression of the cellular receptor of Shiga toxin, the glycosphingolipid Gb 3 (CD77), is significantly increased in colorectal carcinoma and their metastases (4, 5) . Studies on genetic mouse models for human digestive cancer showed that STxB is suitable for noninvasive tumor imaging (6) . STxB is taken up rapidly by tumor cells that express the receptor Gb 3 on their surface membrane, and STxB then follows the so-called retrograde route (7) . The retrograde route bypasses the late endocytic pathway and avoids the degrading environment of the lysosomes. Instead, STxB is transported from the endosome to the trans-Golgi network, then to the Golgi apparatus, and is transported from there to the endoplasmic reticulum (ER) (8) (9) (10) .
It is feasible that STxB has naturally evolved to withstand inactivation by intestinal fluids.
Moreover, STxB has only low immunogenicity in humans (11, 12) . Functionalized STxB can be used efficiently to target gastrointestinal tumors in animal models (6) , as well as short-term primary cultures from human colon cancer and liver metastases (5) . Moreover, a recent study confirmed the findings on Gb 3 overexpression in colon cancer, and reported an up-regulation of Gb 3 expression in human pancreatic cancer patients (13) . In the present study, we have quantified Gb 3 layer chromatography, as well as by immuno-fluorescence microscopy on tissue sections, and tested pancreatic cancer cells for the uptake kinetics of functionalized STxB. Moreover, human astrocytoma xenografts in nude mice are eliminated rapidly, completely, and with long-term efficacy using verotoxin, supporting the concept of therapeutic use of Shiga toxinlike toxins (14) . Recently, successful coupling of STxB to SN38 (7-ethyl-10- hydroxycamptothecin), the active metabolite of the topoisomerase inhibitor Irinotecan (CPT-11), has been reported (15) . SN38 is amenable to biochemical modification, making it a useful candidate drug for a proof of principle approach for STxB-mediated tumor targeting.
Furthermore, SN38 is several orders of magnitude more active than Irinotecan, but its hydrophobicity and insolubility in most physiologically compatible and pharmaceutically acceptable solvents limits its clinical application (16, 17) . Irinotecan has already been reported in several clinical trials as second-line chemotherapy of advanced pancreatic cancer, either as single agent or in combination with gemcitabine or other agents (2, (18) (19) (20) . Anticancer cytotoxicity was reported, even though no obvious survival benefit was reported so far.
The STxB-SN38 compound has been demonstrated previously to possess highly increased cytotoxicity as compared to Irinotecan, when tested on a colorectal cancer cell line (15) .
Moreover, the STxB-SN38 compound showed high receptor-specificity, since the cytotoxic effect relied on an intracellular uptake that is mediated by the receptor Gb 3 . The cytotoxic effect was inhibited when the glycosphingolipid Gb 3 was blocked (15) . Therefore, STxB-SN38 could be a highly useful tool for targeted chemotherapy with greatly enhanced cytotoxicity and low side effects. Informed, written consent regarding the use of tissue samples had been obtained previously, with approval of the local ethics committee. Median follow-up after surgery was 16.9 months. During this period, three patients died due to unrelated causes, 17 died due to cancer progression or disease recurrence. Tumors were classified according to the International Union Against Cancer (UICC), as summarized in Table I (21) . Histology-guided sample selection was performed by a pathologist to identify tumor samples and to exclude cancer cell contamination in the control samples. All samples were snap frozen in liquid nitrogen immediately after resection and stored at -80°C until use.
Reagents and Antibodies
To allow for chemical coupling of fluorophores or cytotoxic drugs to a defined acceptor site in STxB, a Cys residue was added to the CǦterminus of the wildǦtype protein. The recombinant mutant STxBǦCys protein was produced in endotoxin-free form as described (6) .
Antibodies and reagents used were: anti-golgin p97 (Molecular Probes, Karlsruhe, Germany), anti-STxB (22) , anti-CD31 (BD Biosciences Pharmingen, San Diego, CA), DAPI, Ki67, Staurosporine (from Sigma-Aldrich, Munich, Germany), Calnexin, and anti-Vimentin (both from Santa Cruz Biotechnology, Heidelberg, Germany). Secondary antibodies coupled to fluorophores were purchased from Jackson Immunoresearch (West Grove, PA), and cell culture reagents from Invitrogen (Karlsruhe, Germany). Irinotecan was obtained from the Pharmacy of the Klinikum rechts der Isar. SN38 was coupled to STxB as described (15) . Immunostaining was performed as described before (6) . Briefly, after paraformaldehydefixation (PFA), cell lines on cover slips were permeabilized with 0.1% Triton X-100, blocked with PBS containing 2% BSA, and primary antibodies in blocking buffer were added before counterstaining with secondary antibodies. At this concentration, Triton X-100 did not alter the Gb 3 detection on cryosections. STxB was purified from bacteria as previously described (23) 
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RESULTS
Gb 3 -Expression is increased in pancreatic cancer
Previously, we have shown that the glycosphingolipid Gb 3 is over-expressed in human colorectal cancer (5) . Here, we have analyzed surgically resected pancreatic adenocarcinoma and corresponding non-diseased pancreas by lipid extraction and thin layer chromatography.
Gb 3 expression was detectable in all tumors tested (n=28, Table I Figure S1 ) In 48% (13 of 27) of the samples, the Gb 3 level was higher than the calculated median expression of 54.9 ngGb3/mg tissue. In addition, established pancreatic cancer cell lines were tested, and all showed Gb 3 expression ( Figure 1B ). However, Gb 3 expression in cell lines was lower than in primary patient samples. Thus, Gb 3 was clearly up-regulated in pancreatic adenocarcinoma, in good accordance with recent observations (14) . HT29 colon cancer cells, which have been described to bind STxB (16) had 40.9 ng Gb 3 / mg wet weight (not shown), whereas DLD1 colon cancer cells completely lacked Gb 3 . Our statistical analysis showed no correlation between Gb 3 expression and histopathological or survival data. In fact, the hazard ratio for the level of Gb 3 -expression and survival time was 1.005. The correlation with histopathological data involved the tumor size ("pT", p=0.78) and lymph node metastasis status ("pN"-category p=0.52) as well as grading ("G", p=0.21), lymphangiosis (p=0. 19 (5, 6, 27) . Moreover, tumor cells of epithelial origin, as well as tumor-associated blood vessels and stroma are the source of increased Gb 3 expression in colorectal adenocarcinoma (5) . In the present study, tissue from patients with high (n=3) or low Gb 3 expression (n=3) was analyzed by immunohistochemistry ( Fig. 2) , and in parallel, by thin layer chromatography. In spite of different sensitivities both detection methods were in good accordance. In normal pancreas, Gb 3 expression was mainly detected in endothelia (Fig. 2 A-C) . In tumors with low Gb 3 expression, stromal components like blood vessels were the major source of Gb 3 expression (Fig. 2 D-F) . However, in tumors with high Gb 3 expression, duct-like cancer cells were strongly stained with fluorescently labelled STxB (Fig. 2 G-L) . Tumor-associated endothelial cells were only weakly stained for STxB (Fig. 2 F and J) . No association of tumor cell growth with Gb 3 expression was detected in carcinoma with Gb 3 -overexpression (Suppl . Table III) .
However, in carcinoma with low Gb 3 expression, the few cells that were positive for Gb 3 were negative for the proliferation marker Ki67 (Suppl . Table II) . 
Intracellular uptake of STxB in pancreatic cancer cells
allowed binding to the receptor in the absence of cellular uptake, and resulted in STxB staining at the plasma membrane (Fig. 3) . Upon incubation at 37° C, STxB-Cy3 was rapidly internalized and co-localized with the Golgi marker Golgin p97, or with the endoplasmic reticulum marker Calnexin (Fig. 3, Suppl. Fig. S2 and S3 ), indicating that STxB followed the retrograde route to the Golgi apparatus. Two days after the initial uptake, STxB was still detectable in punctate structures, co-localizing with the Golgi in DanG and MiaPaCa2 cells.
However, no obvious co-localization of STxB could be detected with Golgi structures or ER in BxPC3 cells after 48h (Suppl. Fig. S2 ). In accordance with our findings on colorectal cancer cells, we did not observe an induction of apoptosis by STxB in any of the cell lines tested, as evidenced by staining for cleaved Caspase-3 (data not shown). The cell line DLD1, which lacks Gb 3 , did not show STxB binding and uptake (Fig. 3) . The percentage STxBpositive cells was quantified after 60 minutes: 19% of BxPC3, 20% of DanG, 35% of MiaPaCa2, compared to 56% for HT29 colon cancer cells (positive control), and 0% of DLD1 cells (negative control; not shown). Supplementary Fig. 3 shows the distribution of STxBuptake in analyzed cell lines at the tested time points, distinguishing between plasma membrane-, Golgi-and vesicular staining.
STxB specifically delivers a topoisomerase type I inhibitor to pancreatic cancer cells
Since STxB was taken up efficiently by pancreatic cancer cells, we investigated the feasibility of STxB-mediated chemotherapy with a topoisomerase I inhibitor coupled covalently to STxB (15) . SN38 is linked to STxB via a cleavable linker arm that allows for SN38 release from STxB in membrane of the endoplasmic reticulum or Golgi apparatus. On pancreatic cancer cells, the cytotoxic effects of this compound were compared to the effects of the standard drug Irinotecan (Fig. 4) . The left column indicates cell growth in response to increasing concentrations of Irinotecan, the right column shows cell growth after treatment with STxB- Table II , and suppl. Fig. S4 ). The IC 50 (inhibitory concentration 50%) is the concentration that exerts half the specific cytotoxicity.
Moreover, even when cells were treated with the chemotherapeutic agent for only 15 minutes, STxB-SN38 showed a 20-fold greater efficacy than Irinotecan (Suppl. Fig. S5 ). Irinotecan had a cytotoxic effect on DLD1 cells which lack the receptor Gb 3 , whereas STxB-SN38 did not significantly inhibit cell growth (Fig. 4) . At highest concentrations of STxB-SN38, a reduction of cell growth was observable for DLD1 cells, which may be due to non-specific pinocytosis. Figure 5 
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DISCUSSION
In the present work, we demonstrate the use of the non-toxic B-subunit of bacterial Shiga toxin (STxB) for specific targeting of human pancreatic cancer cells. Pancreatic cancer is one of the most aggressive tumor entities and represents the fourth leading cause of cancer related death in Western countries. So far, the only curative therapy is surgery, but due to late diagnosis most patients do not qualify for this treatment. The standard chemotherapy with gemcitabine and chemotherapeutic combinations improves cancer related symptoms, but enhances survival only modestly (2, 20) . Therefore, new options for diagnostic and therapeutic approaches are urgently needed. Previously, we were able to show that STxB allows efficient targeting of colorectal carcinoma, due to an increased expression of its specific receptor, the glycosphingolipid Gb 3 (or CD77) (5, 6) . The binding kinetics of STxB to the receptor Gb 3 are complex. The pentameric STxB has three binding sites per monomer, thus, up to 15 Gb 3 molecules per pentamer are predicted to bind to STxB (7, 28) . When bound to Gb 3 , STxB is internalized and transported to the Golgi apparatus and the endoplasmic reticulum via the retrograde pathway, avoiding degradation in the lysosomes (8) (9) (10) . The protein is detectable in cancer cells for as long as five days (5, 7, 22, 23) .
Consistent with recent data, we detected increased levels of Gb 3 in 78% of pancreatic carcinoma compared to non-diseased pancreas (n=21 of 27 cases) (13). Distler and coworkers reported overexpression of Gb 3 in 62% of pancreatic carcinoma (n=21), based on a newly developed mass spectrometry method (13) . We employed a thin layer chromatography approach, which yielded an absolute quantification of Gb 3 levels, based on wet weight of the tissue samples analyzed (5) . The median expression of Gb 3 for non-diseased pancreas was 29 ng per mg of tissue, as opposed to 55 ng Gb 3 per mg tumor tissue. However, the data reported here show differences to previous reports, which may be explained by the relatively small tissue was statistically highly significant in our case (p=0.0006), but not in a previous study (13) . Gb 3 expression has been reported to lack correlation with any clinico-pathological parameter, except with tumor differentiation (13) . This indicated high levels of Gb 3 in less differentiated tissue. However, we could not confirm a correlation between tumor grading and Gb 3 expression on our collective (p=0.21). Furthermore, our analysis provided no evidence for a correlation of Gb 3 expression with clinical or pathological parameters. Survival analysis showed no significant difference concerning Gb 3 levels. This is in accordance with our earlier findings obtained on colon cancer (6) , and indicates that elevated Gb 3 expression is a frequent phenomenon in malignant gastrointestinal tumors, irrespective of stage and differentiation.
The pathophysiological role of up-regulated Gb 3 expression in tumors is still unclear (29, 30) .
Recently published data show that cisplatin induces Gb3 expression in cancer cells, and that Gb3 expression is linked to acquired cisplatin-resistance (31) . Moreover, increased Gb 3 levels were correlated to increased expression of MDR1/PgP (Multidrug resistant 1/ permeability glycoprotein), a glycoprotein involved in the biosynthesis of glycolipids such as Gb 3 (29) . Gb 3 and MDR1/PgP partially co-localize, with Gb 3 -containing lipid rafts being crucial for intracellular MDR1/PgP surface trafficking. Furthermore, elevated levels of Gb 3 were described in drug resistant cancers (32, 33) and a functional interplay between MDR1/PgP and membrane Gb 3 was suggested.
Importantly, carcinoma cells were the major Gb 3 -source within the tumors. In contrast, the stroma was essentially negative for Gb 3 . Therefore, the large stroma content which is frequently found in pancreatic cancer may lead to an under-estimation of the actual Gb 3 levels. Interestingly, not all tumor cells within one sample were positive for Gb 3 
anti-tumoral immune response caused by dying tumor cells. In the present study, an association of the proliferative status of cancer cells with Gb 3 levels was tested. However, there was no clear correlation of Gb 3 content with the proliferation marker Ki67. The Gb 3 levels found in normal tissue are most likely due to endothelial cells, immune cells, and myofibroblasts, which have been reported to express Gb 3 (24, 34, 35) . We validated the endothelial expression via CD31 staining of tissue sections. Endothelial cells in normal tissue were positive for Gb 3 , intratumoral blood vessels were not strongly marked. However, we and others described a strong Gb 3 expression in tumor-associated neovascularization in human bladder cancer and colorectal carcinoma (35) (36) (37) (38) . Our findings indicate a less pronounced expression of Gb 3 in intratumoral blood vessels in pancreatic cancer, which may result from organ specific variances concerning tumor vascularization. However, it cannot be excluded that Gb 3 may also be expressed by further cells at levels that are below the detection threshold in immunocytochemistry.
Here, we could validate an intracellular uptake along the retrograde pathway in pancreatic cancer cells, whereas no uptake of STxB was observed in DLD1 cells lacking the Gb 3 receptor. Co-localization of fluorescently labeled STxB and the Golgi-marker Golgin p97 occurred within 60 minutes, and intracellular STxB was still detectable after 2 days, even though cell-specific differences were observable at late timepoints. Therefore, targeted chemotherapy mediated by STxB may be feasible on pancreatic cancer. As proof of principle, we utilized a previously established compound that consists of a topoisomerase type I inhibitor, coupled covalently to STxB (16) . SN38 is the active metabolite of Irinotecan, which inhibits the DNA topoisomerase I (16, 17, 39) . Irinotecan is activated by hydrolysis to SN38, but only 2% to 8% of Irinotecan is converted to SN38 in the liver and the tumor cells, which requires higher dosage to obtain therapeutic efficacy (40, 41) . SN38 is far more efficient than Irinotecan, but due to its hydrophobicity and low stability in serum, its clinical use is limited (14, 40, 41) . In vitro, the cytotoxicity was successfully demonstrated for lung, ovarian, colorectal, and gastric cancer, and several trials investigate the clinical use of the agent (16, 17, 39, (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) . Covalent coupling to STxB could be an effective means to stabilize SN38 (15) , and has the advantage of greatly enhanced specificity. Only cells which express the Gb 3 receptor are targeted, and consequently, the clinical side effects could be expected to be greatly diminished. Endothelial cells or kidney epithelia express Gb 3 and might therefore be negatively affected by a cytotoxic STxB-based compound (44, 45) . However, although Gb 3 levels and Shiga toxin (STx) binding does not change depending on patients age, the effects, in particular the hemolytic uremic syndrome, appear age dependent. Therefore the renal damage caused by STx and conclusively in case of therapeutic usage of STxB the possible renal side effects cannot be estimated yet and should be evaluated (46) .
The standard therapy for pancreatic cancer is gemcitabine (2, 3, 47, 48) . However, Irinotecan is currently analyzed as first-, second-, and third-line therapy for advanced and metastatic pancreatic cancer in gemcitabine refractory cases, and showed slight but objective responses as single agent, or in combination (FOLFIRI) (21, 49, 50) . We therefore decided to test STxB-SN38 as a novel therapeutic compound on pancreatic cancer cells. As positive control, STxB-SN38 was tested on the Gb 3 -expressing colon cancer cell line HT29 (15) . Proliferation assays demonstrated cytotoxicity of STxB-SN38 on HT29 cells (not shown). To validate the receptor-specificity, tests were performed on DLD1, a Gb 3 -negative colon cancer cell line.
Reduced cytotoxicity was observed for STxB-SN38, whereas the cells responded to Irinotecan. All pancreatic cancer cell lines tested were sensitive to treatment with Irinotecan or STxB-SN38. Importantly, STxB-SN38 had a significantly stronger cytotoxic effect than Irinotecan; the IC 50 values for STxB-SN38 were enhanced over 100-fold as compared to Irinotecan, in accordance with earlier findings on colorectal cancer cells (15) (Fig. 4, Table 2 ). 
